A Study of ABT-751 in Patients With Renal Cell Cancer

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott

Criteria

Inclusion Criteria

• Renal Cell Carcinoma.

• Recurrent tumor.

• At least 6 weeks post-nephrectomy.

• Able to tolerate normal activities of daily living.

• Adequate bone marrow, kidney, and liver function.

Exclusion Criteria

• Pregnant or breast feeding.

• Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.

• CNS metastasis.